Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors
Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.
Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the mechanism of action through a specific immune response, and validate the anti-tumor effects of STC-1010.
These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer.
The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models. Dendritic cells primed by STC-1010 will induce a multi specific pool of T-lymphocytes against the tumor without toxicity.
The second study evaluated the functional activity of STC-1010-primed dendritic cells (DCs) from PBMCs human donors’ isolation, to activate autologous CD8+ T cells and promote tumor cell death. The study evaluated the cross-priming and specificity of the immune response induced by STC-1010. Results showed that STC-1010 is an efficient strategy to educate the immune system by cross-priming DCs and increasing the activity of specific CD8+ T cells (TCR sequencing) all of which promotes the significant tumor killing observed ex-vivo.
Taken together, these studies provide promising results for the development of the STC-1010 and prove its potential to be presented into clinical setting for the treatment of patients with CRC.
Innovative in vivo model for anti-tumor vaccine development: Safety validation and preliminary efficacy evaluation of a new antitumor vaccine STC-1010 on human colorectal adenocarcinoma using the chicken CAM assay.
Session Title: Clinical Research Excluding Trials - Vaccines
Abstract Presentation Number: 6791
- Yan WANG, email@example.com Scientist/R&D Project Manager2 (PhD)
- Arnaud PEYRONNIER, firstname.lastname@example.org, Sales Director4 (MSc)
- Benoit PINTEUR, email@example.com, Chief Scientific Officer3 (Pharm D)
- Lionel CHALUS, firstname.lastname@example.org, Chief Scientific Officer5
- Corinne TORTORELLI, email@example.com, Medical Lead5 (Pharm. D., Ph.D)
- Paul BRAVETTI, firstname.lastname@example.org, Chief Executive Officer5 (Pharm D, MSc)
- Jean VIALLET, email@example.com, Chief Executive Officier4 (PhD)
- François GHIRINGHELLI FGhiringhelli@cgfl.fr, Head of Team Inserm 1231 TIRECs « Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology4 (M.D, PhD)
STC-1010 a new therapeutic vaccine promotes tumor cell death.
Session Title: Late-Breaking Research: Immunology 2
Abstract Presentation Number: LB224
- Alban BESSEDE, firstname.lastname@example.org, Chief Executive Officer5 (Ph.D)
- George ALZEEB, email@example.com, Scientific Project Manager5 (Ph.D)
- Corinne TORTORELLI, firstname.lastname@example.org, Medical Lead5 (Pharm.D., Ph.D)
- Jean-Philippe GUEGUAN, email@example.com, Study Director7
- Christophe REY, firstname.lastname@example.org 7
- Lionel CHALUS, email@example.com, Chief Scientific Officer5
- Benoit PINTEUR, firstname.lastname@example.org, Chief Scientific Officer5 (Pharm D)
- Paul BRAVETTI, email@example.com,Chief Executive Officer5(Pharm D, MSc)
- Antoine ITALIANO, firstname.lastname@example.org, Early Phase Trials and Sarcoma Units,6(M.D, Ph.D)
For further information:
STC-1010 is a next-generation cancer vaccine immunotherapy that targets tumor antigens and is produced by Allogeneic STC's proprietary Brenus platform. It’s the lead candidate specifically designed to combat colorectal cancer (CRC) including MSS and MSI-H populations in its first line of treatment for the first indication.
2 Inovotion Biopolis- 5 av du Grand Sablon, 38700 La Tronche, France
3 Brenus Pharma Parc industriel Tech Lavaur La Bechade 63 500 Issoire, France
4 Center Georges François Leclerc, 1 rue du Pr Marion 21000 Dijon, France
5 Explicyte 229 Cours de l'Argonne, 33000 Bordeaux
6 Institut Bergonie 229 Cours de l'Argonne, 33000 Bordeaux
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005544/en/
+ 33 (0)7 87 76 87 72
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Completed Divestiture of Savory Solutions Business31.5.2023 23:15:00 EEST | Press release
IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Savory Solutions business unit to PAI Partners (PAI), a leading global private equity firm with a strong focus on the food and consumer industry. Under PAI ownership, Savory Solutions Group has been rebranded to NovaTaste, a global leader in taste innovation with headquarters in Salzburg, Austria. “The sale of IFF’s Savory Solutions Group represents our continued efforts to optimize our portfolio as we focus on core businesses and strengthen our capital structure,” said Frank Clyburn, IFF CEO. “We remain steadfast in our commitment to further pursue portfolio optimization opportunities as we drive toward our deleverage target by the end of 2024. We’re grateful to our Savory Solutions colleagues, who have demonstrated their commitment to innovation, service and quality. We wish them the best in their new journey.” Cautionary Statement under the Private Securities Litigation Refo
UAE Pledges Additional $2.7bn in Industry Offtake Agreements, Invites Global Investors to Leverage Incentives31.5.2023 21:13:00 EEST | Press release
His Excellency Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, today announced $2.7 billion in offtake agreements for the UAE’s industrial sector in a move to boost local manufacturing, strengthen supply chains and attract international investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005894/en/ His Excellency Dr Sultan Al Jaber UAE Minister of Industry and Advanced Technology (Photo: AETOSWire) Addressing the second Make it in the Emirates Forum, HE Dr. Al Jaber said the new set of procurement opportunities would build on the previous forum’s offtake agreements. “One of the key achievements of last year’s forum was several leading national companies announcing their intention to invest $29.9 billion over the next decade to purchase 300 products from local manufacturers,” HE Dr. Al Jaber said. “I am pleased to share with you that in the first year alone, 28 percent of these offtake agreement
Carbios Will Receive Grants Totaling €54 Million From French State via France 2030 and Grand-Est Region1 to Finance Construction of World's First PET Biorecycling Plant and Accelerate R&D Activities31.5.2023 19:30:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005830/en/ Carbios will receive grants totaling €54 million from French State via France 2030 and Grand-Est Region to finance construction of world's first PET biorecycling plant and accelerate R&D activities (Photo: Carbios) Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, announces that its project has been selected by the French State for funding of €30 million from the French State as part of the investment plan France 2030, and €12.5 million from the Grand-Est Region. The implementation of this funding is conditional to the European Commission's approval of the corresponding state aid scheme, followed by the conclusion of national aid agreements. As part of the national call for projects on "Plastics Recycling" operated by ADEM
SellerX to Acquire Elevate Brands, Creating One of the World’s Leading eCommerce Aggregators31.5.2023 18:00:00 EEST | Press release
SellerX, one of the most successful eCommerce aggregators in Europe, has signed an agreement to acquire Elevate Brands, a leading U.S.-based aggregator of eCommerce businesses. The combined companies will form SellerX Group and become one of the world’s largest consolidators of eCommerce brands with a diversified portfolio spanning over 40,000 consumer products. The combined business will have a strong global footprint and sales of over €400m. This acquisition brings together two key players in the aggregator space, each of which have established themselves as highly trusted and reputable partners for marketplace-native sellers in their respective markets. Bringing together complementary global footprints, the joint business will cover both the European and U.S.-markets with a roughly even revenue split across the two regions. The combined brand portfolio will consist of over 80 Amazon-native private label consumer brands in the segments of sports & outdoors, home & kitchen, mobile acc
PPG sets science-based 2030 decarbonization targets, reports 2022 sustainability progress31.5.2023 17:15:00 EEST | Press release
PPG (NYSE:PPG) today announced its near-term 2030 sustainability goals, including greenhouse gas (GHG) emissions targets that have been validated by the Science Based Targets initiative (SBTi). The company also marked strong progress against its environmental, social and governance (ESG) priorities, reporting increased sales of sustainably advantaged products, more efficient operations, strong momentum towards achieving diversity, equity and inclusion goals, greater supplier sustainability and strengthened support within communities where the company operates. “PPG has long been committed to reducing the environmental impact of its own operations, and we are proud to have validated science-based GHG emissions targets that are in line with the expectations of the Paris Agreement,” said Diane Kappas, PPG vice president, global sustainability. “By raising our sustainability ambitions and increasing sales of sustainable solutions for our customers, PPG is advancing its leadership in the pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom